ES2535654T3 - ADN triciclo-fosforotioato - Google Patents
ADN triciclo-fosforotioato Download PDFInfo
- Publication number
- ES2535654T3 ES2535654T3 ES11185129.1T ES11185129T ES2535654T3 ES 2535654 T3 ES2535654 T3 ES 2535654T3 ES 11185129 T ES11185129 T ES 11185129T ES 2535654 T3 ES2535654 T3 ES 2535654T3
- Authority
- ES
- Spain
- Prior art keywords
- dna
- nucleic acid
- acid molecule
- mrna
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11185129.1A EP2581448B1 (en) | 2011-10-13 | 2011-10-13 | Tricyclo-phosphorothioate DNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2535654T3 true ES2535654T3 (es) | 2015-05-13 |
Family
ID=44799824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11185129.1T Active ES2535654T3 (es) | 2011-10-13 | 2011-10-13 | ADN triciclo-fosforotioato |
| ES12770503.6T Active ES2651216T3 (es) | 2011-10-13 | 2012-10-12 | Triciclo-ADN fosforotioato |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12770503.6T Active ES2651216T3 (es) | 2011-10-13 | 2012-10-12 | Triciclo-ADN fosforotioato |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9738891B2 (enExample) |
| EP (2) | EP2581448B1 (enExample) |
| JP (1) | JP6181653B2 (enExample) |
| CN (1) | CN104245935B (enExample) |
| AU (1) | AU2012322903B2 (enExample) |
| BR (1) | BR112014009066B8 (enExample) |
| CA (2) | CA2776651C (enExample) |
| DK (1) | DK2581448T3 (enExample) |
| ES (2) | ES2535654T3 (enExample) |
| IL (1) | IL231983B (enExample) |
| IN (1) | IN2014DN03463A (enExample) |
| PL (1) | PL2581448T3 (enExample) |
| PT (1) | PT2581448E (enExample) |
| WO (1) | WO2013053928A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1766010T3 (pl) | 2004-06-28 | 2011-07-29 | Univ Western Australia | Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| CN105779453A (zh) | 2008-10-24 | 2016-07-20 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| BR122023023194A2 (pt) | 2009-11-12 | 2023-12-26 | The University Of Western Australia | Oligonucleotídeo antissentido, composição e respectivo uso |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| EA202090946A3 (ru) | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии |
| NZ631289A (en) | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| KR102275504B1 (ko) | 2013-09-05 | 2021-07-09 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함 |
| WO2015036451A1 (en) | 2013-09-11 | 2015-03-19 | Synthena Ag | Nucleic acids and methods for the treatment of pompe disease |
| US10590420B2 (en) | 2014-07-31 | 2020-03-17 | Association Institut De Myologie | Treatment of amyotrophic lateral sclerosis |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US20180237775A1 (en) | 2015-09-21 | 2018-08-23 | Association Institut De Myologie | Antisense oligonucleotides and uses thereof |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| MY200252A (en) | 2016-04-18 | 2023-12-16 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| WO2017190041A1 (en) | 2016-04-29 | 2017-11-02 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
| MX383656B (es) | 2016-05-24 | 2025-03-14 | Sarepta Therapeutics Inc | Procesos para preparar oligómeros de morfolino fosforodiamidato. |
| SG10202101834QA (en) | 2016-05-24 | 2021-04-29 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| SG10202101830WA (en) | 2016-05-24 | 2021-04-29 | Sarepta Therapeutics Inc | Processes for preparing oligomers |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| IL263044B2 (en) | 2016-05-24 | 2024-06-01 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| AU2017290231A1 (en) | 2016-06-30 | 2019-02-07 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| CA3037663A1 (en) | 2016-09-23 | 2018-03-29 | Synthena Ag | Mixed tricyclo-dna, 2'-modified-rna oligonucleotide compositions and uses thereof |
| WO2018055577A1 (en) | 2016-09-23 | 2018-03-29 | Synthena Ag | Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof |
| LT3554553T (lt) | 2016-12-19 | 2022-08-25 | Sarepta Therapeutics, Inc. | Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos |
| CN117298290A (zh) | 2016-12-19 | 2023-12-29 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
| EP3554552B1 (en) | 2016-12-19 | 2022-08-17 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CN110536694A (zh) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| CA3059321A1 (en) * | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
| WO2018193428A1 (en) | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| EP3687577A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| JP2020536057A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| IL321667A (en) | 2018-12-13 | 2025-08-01 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| US20220193246A1 (en) | 2019-04-18 | 2022-06-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| WO2021089736A1 (en) | 2019-11-06 | 2021-05-14 | Association Institut De Myologie | Combined therapy for muscular diseases |
| PH12022552258A1 (en) | 2020-02-28 | 2023-11-20 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating smn2 |
| JP7787094B2 (ja) | 2020-04-09 | 2025-12-16 | アソシエーション・アンスティトゥート・ドゥ・マイオロジー | 筋萎縮性側索硬化症を治療するためのアンチセンス配列 |
| EP3978608A1 (en) | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51 |
| JP2024537711A (ja) | 2021-09-30 | 2024-10-16 | サレプタ セラピューティクス， インコーポレイテッド | １つ以上の脱塩基ユニットを有するアンチセンスオリゴヌクレオチド |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| JP2025533454A (ja) | 2022-09-21 | 2025-10-07 | サレプタ セラピューティクス， インコーポレイテッド | Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率 |
| TW202442246A (zh) | 2023-04-27 | 2024-11-01 | 美商薩羅塔治療公司 | 用於治療慢性腎病之反義寡聚物 |
| AU2024362420A1 (en) | 2023-10-18 | 2026-04-23 | Murdoch University | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| CA2315256A1 (en) | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| JP2002537828A (ja) | 1999-03-10 | 2002-11-12 | フォゲン リミティド | 細胞への物質のデリバリー |
| MXPA05011022A (es) * | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| MX2009002859A (es) * | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009005793A2 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| JP2012509366A (ja) * | 2008-11-17 | 2012-04-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 核酸送達系のための放出可能ポリマー脂質 |
| JP2012523225A (ja) * | 2009-04-10 | 2012-10-04 | アソシアシオン・アンスティテュ・ドゥ・ミオロジー | 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法 |
| CN103477273A (zh) | 2011-02-25 | 2013-12-25 | 卢米泰克斯公司 | 显示器前方照明装置 |
-
2011
- 2011-10-13 EP EP11185129.1A patent/EP2581448B1/en active Active
- 2011-10-13 ES ES11185129.1T patent/ES2535654T3/es active Active
- 2011-10-13 PT PT111851291T patent/PT2581448E/pt unknown
- 2011-10-13 PL PL11185129T patent/PL2581448T3/pl unknown
- 2011-10-13 DK DK11185129T patent/DK2581448T3/en active
-
2012
- 2012-04-27 CA CA2776651A patent/CA2776651C/en active Active
- 2012-10-12 JP JP2014535113A patent/JP6181653B2/ja active Active
- 2012-10-12 AU AU2012322903A patent/AU2012322903B2/en active Active
- 2012-10-12 CA CA2851970A patent/CA2851970A1/en not_active Abandoned
- 2012-10-12 EP EP12770503.6A patent/EP2766479B1/en active Active
- 2012-10-12 WO PCT/EP2012/070349 patent/WO2013053928A1/en not_active Ceased
- 2012-10-12 BR BR112014009066A patent/BR112014009066B8/pt active IP Right Grant
- 2012-10-12 ES ES12770503.6T patent/ES2651216T3/es active Active
- 2012-10-12 US US14/351,733 patent/US9738891B2/en active Active
- 2012-10-12 CN CN201280057688.6A patent/CN104245935B/zh active Active
-
2014
- 2014-04-07 IL IL231983A patent/IL231983B/en active IP Right Grant
- 2014-04-30 IN IN3463DEN2014 patent/IN2014DN03463A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012322903A1 (en) | 2014-05-29 |
| BR112014009066A2 (pt) | 2017-04-18 |
| CN104245935A (zh) | 2014-12-24 |
| DK2581448T3 (en) | 2015-04-27 |
| PL2581448T3 (pl) | 2015-08-31 |
| EP2581448B1 (en) | 2015-01-28 |
| EP2766479A1 (en) | 2014-08-20 |
| US20140296323A1 (en) | 2014-10-02 |
| CN104245935B (zh) | 2018-05-08 |
| CA2776651A1 (en) | 2013-04-13 |
| EP2581448A1 (en) | 2013-04-17 |
| AU2012322903B2 (en) | 2017-09-14 |
| BR112014009066A8 (pt) | 2018-01-09 |
| ES2651216T3 (es) | 2018-01-25 |
| CA2776651C (en) | 2021-06-08 |
| WO2013053928A1 (en) | 2013-04-18 |
| US9738891B2 (en) | 2017-08-22 |
| BR112014009066B1 (pt) | 2020-08-25 |
| IN2014DN03463A (enExample) | 2015-06-05 |
| CA2851970A1 (en) | 2013-04-18 |
| BR112014009066B8 (pt) | 2021-02-23 |
| JP2015501144A (ja) | 2015-01-15 |
| IL231983B (en) | 2018-04-30 |
| JP6181653B2 (ja) | 2017-08-16 |
| PT2581448E (pt) | 2015-05-21 |
| EP2766479B1 (en) | 2017-09-13 |
| IL231983A0 (en) | 2014-05-28 |
| HK1186205A1 (en) | 2014-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2651216T3 (es) | Triciclo-ADN fosforotioato | |
| ES2551154T3 (es) | Procedimiento para la eficiente omisión del exón (44) en distrofia muscular de Duchenne y medios asociados | |
| ES2573981T3 (es) | Oligonucleótidos antisentido de triciclo-ADN, composiciones, y métodos para el tratamiento de enfermedades | |
| DK2850186T3 (en) | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION | |
| ES2700277T3 (es) | Agentes de doble cadena para el suministro de oligonucleótidos terapéuticos | |
| ES2699827T3 (es) | Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto | |
| ES2566553T3 (es) | ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares | |
| ES2707232T3 (es) | Acido nucleico bicatenario quimérico | |
| ES2935658T3 (es) | Compuestos y métodos para la modulación de SMN2 | |
| US12178855B2 (en) | Compositions and methods for facilitating delivery of synthetic nucleic acids to cells | |
| CN104540946A (zh) | 用于调节utrn表达的组合物和方法 | |
| JP2019527549A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| ES2918975T3 (es) | Tratamiento de la distrofia facioescapulohumeral | |
| WO2019183005A1 (en) | 2'f-ana-let7 mediated utrophin upregulation for dmd therapy | |
| CN107466323A (zh) | 酰基‑氨基‑lna和/或烃基‑氨基‑lna寡核苷酸 | |
| JP7536187B2 (ja) | 核内受容体サブファミリー１グループｈメンバー３（ｎｒ１ｈ３）発現を阻害するための組成物および方法 | |
| HK1186205B (en) | Tricyclo-phosphorothioate dna | |
| Leumann et al. | des brevets (11) GG 0 000 000 L0 (12) LLLLLGGG GGGGGGGG LLLLL GGGGGGGG | |
| EP4426839A1 (en) | Lipid conjugation for targeting astrocytes of the central nervous system | |
| CN121793974A (zh) | 用于治疗肌少症的组合物和方法 | |
| WO2024233864A2 (en) | Galnac-conjugated rnai oligonucleotides | |
| WO2023081822A1 (en) | Lipid conjugation for targeting oligodendrocytes of the central nervous system | |
| BR122020025437B1 (pt) | Uso de um conjugado de oligômero antissenso para tratar distrofia muscular de duchenne | |
| BR112019012647B1 (pt) | Conjugados de oligômero antissenso que induzem o salto de éxon 51 no gene da distrofia humana |